Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy

NeuroToxicology

Volumn 31, Issue 6, 2010, Pages 694-700

  Sittl, Ruth ^a   Carr, Richard W ^a   Fleckenstein, Johannes ^a   Grafe, Peter ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Axonal hyperexcitability; Cold allodynia; Oxaliplatin; Potassium channel activator; Threshold tracking

Indexed keywords

FLUPIRTINE; OXALIPLATIN;

ACTION POTENTIAL; ACUTE DISEASE; ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EXPOSURE; DRUG MECHANISM; IN VITRO STUDY; MALE; NERVE EXCITABILITY; NERVE FIBER; NEUROPATHY; NONHUMAN; PERIPHERAL NERVE; POTASSIUM CONDUCTANCE; PRIORITY JOURNAL; RAT; STIMULUS;

ACTION POTENTIALS; ACUTE DISEASE; AGED; ANIMALS; AXONS; ELECTRIC STIMULATION; FEMALE; HUMANS; MALE; NEURAL CONDUCTION; ORGAN CULTURE TECHNIQUES; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; POTASSIUM CHANNELS, VOLTAGE-GATED; RATS; RATS, WISTAR; SURAL NERVE; UP-REGULATION;

RATTUS; RODENTIA;

EID: 78049455364     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2010.07.006     Document Type: Article

References (59)

1. Adams P.R., Brown D.A., Constanti A. M-currents and other potassium currents in bullfrog sympathetic neurones. J. Physiol. 1982, 330:537-572.
2. Adelsberger H., Quasthoff S., Grosskreutz J., Lepier A., Eckel F., Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur. J. Pharmacol. 2000, 40:25-32.
3. Ali B.H. Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature. Basic Clin. Pharmacol. Toxicol. 2009, 106:272-279.
4. Argyriou A.A., Polychronopoulos P., Iconomou G., Chroni E., Kalofonos H.P. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat. Rev. 2008, 34:368-377.
5. Baker M., Bostock H., Grafe P., Martius P. Function and distribution of three types of rectifying channel in rat spinal root myelinated axons. J. Physiol. 1987, 383:45-67.
6. Benedict F.G., Miles W.R., Johnson A. The temperature of the human skin. Proc. Natl. Acad. Sci. U.S.A. 1919, 5:218-222.
7. Benoit E., Brienza S., Dubois J.M. Oxaliplatin an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons. Gen. Physiol. Biophys. 2006, 25:263-276.
8. Bergmans J. The Physiology of Single Human Nerve Fibres 1970, Louvain, Vander.
9. Bostock H., Cikurel K., Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998, 21:137-158.
10. Brown D.A., Passmore G.M. Neural KCNQ (Kv7) channels. Br. J. Pharmacol. 2009, 156:1185-1195.
11. Carr R.W., Sittl R., Fleckenstein J., Grafe P. GABA increases electrical excitability in a subset of human unmyelinated peripheral axons. PLoS One 2010, 5:e8780.
12. Cobet R. Die Hauttemperatur des Menschen. Erg. Physiol. 1926, 25:438-516.
13. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18:2938-2947.
14. Devaux J.J., Kleopa K.A., Cooper E.C., Scherer S.S. KCNQ2 is a nodal K+ channel. J. Neurosci. 2004, 24:1236-1244.
15. Durand J.P., Brezault C., Goldwasser F. Protection against oxaliplatin acute neurosensory toxicity by venlafaxine. Anticancer Drugs 2003, 14:423-425.
16. Extra J.M., Marty M., Brienza S., Misset J.L. Pharmacokinetics and safety profile of oxaliplatin. Semin. Oncol. 1998, 25:13-22.
17. Friedel H.A., Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993, 45:548-569.
18. Gamelin E., Gamelin L., Bossi L., Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin. Oncol. 2002, 29:21-33.
19. Gamelin L., Boisdron-Celle M., Delva R., Guerin-Meyer V., Ifrah N., Morel A., et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res. 2004, 10:4055-4061.
20. Gamelin L., Boisdron-Celle M., Morel A., Poirier A.L., Berger V., Gamelin E., et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J. Clin. Oncol. 2008, 26:1188-1189.
21. Goodchild C.S., Kolosov A., Tucker A.P., Cooke I. Combination therapy with flupirtine and opioid: studies in rat pain models. Pain Med. 2008, 9:928-938.
22. Goodchild C.S., Nelson J., Cooke I., Ashby M., Jackson K. Combination therapy with flupirtine and opioid: open-label case series in the treatment of neuropathic pain associated with cancer. Pain Med. 2008, 9:939-949.
23. Grolleau F., Gamelin L., Boisdron-Celle M., Lapied B., Pelhate M., Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol. 2001, 85:2293-2297.
24. Hlavica P., Niebch G. Pharmacokinetics and biotransformation of the analgesic flupirtine in humans. Arzneimittelforschung 1985, 35:67-74.
25. Hochster H.S., Grothey A., Childs B.H. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J. Clin. Oncol. 2007, 25:4028-4029.
26. Ishibashi K., Okada N., Miyazaki T., Sano M., Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int. J. Clin. Oncol. 2010, 15:82-87.
27. Kagiava A., Tsingotjidou A., Emmanouilides C., Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 2008, 29:1100-1106.
28. Kang D., Choe C., Kim D. Thermosensitivity of the two-pore domain K+ channels TREK-2 and TRAAK. J. Physiol. 2005, 564:103-116.
29. Kiernan M.C., Krishnan A.V. The pathophysiology of oxaliplatin-induced neurotoxicity. Curr. Med. Chem. 2006, 13:2901-2907.
30. Klawe C., Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Expert. Opin. Pharmacother. 2009, 10:1495-1500.
31. Kocsis J.D., Eng D.L., Gordon T.R., Waxman S.G. Functional differences between 4-aminopyridine and tetraethylammonium-sensitive potassium channels in myelinated axons. Neurosci. Lett. 1987, 75:193-198.
32. Kornhuber J., Bleich S., Wiltfang J., Maler M., Parsons C.G. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid Commun. J. Neural Transm. 1999, 106:857-867.
33. Kowalski T., Maier C., Reinacher-Schick A., Schlegel U. Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options. Schmerz 2008, 22:16-23.
34. Krishnan A.V., Goldstein D., Friedlander M., Kiernan M.C. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005, 32:51-60.
35. Krishnan A.V., Goldstein D., Friedlander M., Kiernan M.C. Oxaliplatin and axonal Na+ channel function in vivo. Clin. Cancer Res. 2006, 12:4481-4484.
36. Lang P.M., Fleckenstein J., Passmore G.M., Brown D.A., Grafe P. Retigabine reduces the excitability of unmyelinated peripheral human axons. Neuropharmacology 2008, 54:1271-1278.
37. Lange B. Über den Einfluss bewegter Luft auf das thermische Verhalten des Menschen. Med. Microbiol. Immunol. 1921, 91:473-497.
38. Lehky T.J., Leonard G.D., Wilson R.H., Grem J.L., Floeter M.K. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387-392.
39. Maingret F., Lauritzen I., Patel A.J., Heurteaux C., Reyes R., Lesage F., et al. TREK-1 is a heat-activated background K(+) channel. EMBO J. 2000, 19:2483-2491.
40. Maurer K., Bostock H., Koltzenburg M. A rat in vitro model for the measurement of multiple excitability properties of cutaneous axons. Clin. Neurophysiol. 2007, 118:2404-2412.
41. Miceli F., Soldovieri M.V., Martire M., Taglialatela M. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. Curr. Opin. Pharmacol. 2008, 8:65-74.
42. Nikcevich D.A., Grothey A., Sloan J.A., Kugler J.W., Silberstein P.T., Dentchev T., et al. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: results of the phase III placebo-controlled, double-blind NCCTG trial NO4CT. J. Clin. Oncol. 2008, 26(Suppl.). abstr4009.
43. Park S.B., Goldstein D., Lin C.S., Krishnan A.V., Friedlander M.L., Kiernan M.C. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J. Clin. Oncol. 2009, 27:1243-1249.
44. Passmore G.M., Selyanko A.A., Mistry M., Al Qatari M., Marsh S.J., Matthews E.A., et al. KCNQ/M currents in sensory neurons: significance for pain therapy. J. Neurosci. 2003, 23:7227-7236.
45. Pederiva S., Caspar C.B. Management of acute oxaliplatin-related peripheral sensory neuropathy with magnesium and calcium. Proc. Am. Soc. Clin. Oncol. 2006, 22 abstr3715.
46. Quasthoff S., Hartung H.P. Chemotherapy-induced peripheral neuropathy. J. Neurol. 2002, 249:9-17.
47. Rivera-Arconada I., Roza C., Lopez-Garcia J.A. Enhancing m currents: a way out for neuropathic pain?. Front Mol. Neurosci. 2009, 2:10.
48. Roza C., Lopez-Garcia J.A. Retigabine, the specific KCNQ channel opener, blocks ectopic discharges in axotomized sensory fibres. Pain 2008, 138:537-545.
49. Rudolph S., Ridwelski K., Kuhn R., Lippert H. Randomized trial with or without aminofostin to reduce neurotoxicity side effects under chemotherapy with oxaliplatin (L-OHP), FA/5-FU. Ann. Oncol. 2000, 11(Suppl. 4). abstr708P.
50. Saadati H., Saif M.W. Oxaliplatin-induced hyperexcitability syndrome in a patient with pancreatic cancer. JOP 2009, 10:459-461.
51. + current regulating excitability in the rat node of Ranvier. J. Physiol. 2006, 573:17-34.
52. Sittl R., Carr R.W., Schwarz J.R., Grafe P. The Kv7 potassium channel activator flupirtine affects clinical excitability parameters of myelinated axons in isolated rat sural nerve. J. Peripher. Nerv. Syst. 2010, 15:63-72.
53. Thomas R.C. Electrogenic sodium pump in nerve and muscle cells. Physiol. Rev. 1972, 52:563-594.
54. von Delius S., Eckel F., Wagenpfeil S., Mayr M., Stock K., Kullmann F., et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 2007, 25:173-180.
55. Webster R.G., Brain K.L., Wilson R.H., Grem J.L., Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 2005, 146:1027-1039.
56. Windebank A.J., Grisold W. Chemotherapy-induced neuropathy. J. Peripher. Nerv. Syst. 2008, 13:27-46.
57. Wrzesinski S.H., McGurk M.L., Donovan C.T., Ferencz T.M., Saif M.W. Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate. Anticancer Drugs 2007, 18:721-724.
58. Wu S.N., Chen B.S., Wu Y.H., Peng H., Chen L.T. The mechanism of the actions of oxaliplatin on ion currents and action potentials in differentiated NG108-15 neuronal cells. Neurotoxicology 2009, 30:677-685.
59. Xiong Q., Gao Z., Wang W., Li M. Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds. Trends Pharmacol. Sci. 2008, 29:99-107.